Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioAtla, Inc. before investing.

In this article, we go over a few key elements for understanding BioAtla, Inc.’s stock price such as:

• BioAtla, Inc.’s current stock price and volume
• Why BioAtla, Inc.’s stock price changed recently
• Upgrades and downgrades for BCAB from analysts
• BCAB’s stock price momentum as measured by its relative strength

About BioAtla, Inc. (BCAB)

Before we jump into BioAtla, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Want to learn more about BioAtla, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioAtla, Inc..

What Caused BioAtla, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded BioAtla, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BioAtla, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioAtla, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioAtla, Inc. (BCAB) by visiting AAII Stock Evaluator.

Relative Price Strength of BioAtla, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, BioAtla, Inc. has a weighted four-quarter relative price strength of 28.84%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how BioAtla, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioAtla, Inc. Stock Price: Bottom Line

As of December 1, 2025, BioAtla, Inc.’s stock price is $0.796, which is down 11.99% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioAtla, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.